Allegria Therapeutics

Allegria Therapeutics is a Swiss biotechnology company founded in 2023 and based in Basel. The company focuses on developing a differentiated portfolio of proprietary therapeutic approaches and biological targets designed to selectively modulate mast cells. By targeting these specific cells, which play a central role in driving allergic and inflammatory conditions, the company aims to create transformative therapies with the potential for first-in-class performance. The organization was established by Forty51 Ventures and is led by CEO and co-founder Maria van Dongen, who brings extensive experience in pharmaceutical R&D and external partnerships.

The company's mission is to address the significant and growing global burden of allergy and mast cell-mediated inflammatory diseases, where current treatment options often provide inadequate outcomes. Through collaborations with leading experts in fundamental mast cell biology and preclinical evaluation, such as researchers from Charité and the Medical University of Vienna, Allegria is advancing its R&D pipeline. The company has secured several rounds of seed financing, including contributions from investors like Forty51 Ventures and ALK-Abelló, to support its efforts to improve patient quality of life through specialized, selective therapeutic interventions.